Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $103,147.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $24.27, for a total value of $103,147.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total value of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total value of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total value of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $75,210.00.

Enliven Therapeutics Stock Performance

ELVN stock opened at $26.00 on Wednesday. The stock has a market cap of $1.22 billion, a P/E ratio of -13.47 and a beta of 1.09. The firm has a 50 day simple moving average of $23.14 and a 200 day simple moving average of $21.71. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ELVN shares. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target for the company. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ELVN. Quest Partners LLC grew its stake in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after buying an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after acquiring an additional 3,189 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after purchasing an additional 8,540 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Enliven Therapeutics during the 1st quarter valued at $167,000. Finally, Rhumbline Advisers lifted its stake in shares of Enliven Therapeutics by 29.9% in the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock valued at $1,160,000 after purchasing an additional 11,420 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.